COVID-19重症ICU患者全球预后系统评价与荟萃分析
汇总显示ICU患者院内死亡率为28.1%(95%CI 23.4-33.0),ARDS发生率达76.1%,需大量器官支持且ICU及住院时间延长。
要点
- ICU收治的COVID-19患者院内死亡率为28.1%(95%CI 23.4-33.0)
- 76.1%发生ARDS,67.7%需有创机械通气,65.9%需血管活性药
- ICU和住院时间分别为10.8天和19.1天,器官支持需求高
核心结论
- ICU收治的COVID-19危重患者需要大量器官支持及较长的ICU和住院治疗。
- 全球重症COVID-19汇总病死率低于三分之一,院内死亡率为28.1%(95%CI 23.4-33.0)。
研究设计与样本
- 系统评价与荟萃分析,检索Medline、Embase和Cochrane图书馆至2020年8月1日。
- 采用随机效应模型计算汇总患病率,亚组分析基于地理分布、研究类型、质量评估、样本量、结束日期和患者去向。
- 使用纽卡斯尔-渥太华量表对非随机研究进行批判性评价。
主要发现
- 患者平均年龄62.6岁(95%CI 60.4-64.7),常见合并症为高血压49.5%(95%CI 44.9-54.0)和糖尿病26.6%(95%CI 22.7-30.8)。
- ARDS发生率为76.1%(95%CI 65.7-85.2),有创机械通气需求67.7%(95%CI 59.1-75.7),血管活性药支持65.9%(95%CI 52.4-78.4)。
- 肾脏替代治疗16.9%(95%CI 12.1-22.2),体外膜氧合6.4%(95%CI 4.1-9.1)。
- ICU入住时间10.8天(95%CI 9.3-18.4),住院时间19.1天(95%CI 16.3-21.9),院内死亡率28.1%(95%CI 23.4-33.0;I2=96%)。
- 未观察到显著的亚组效应。
临床怎么用
- 呼吸科医生应认识到ICU收治的COVID-19患者器官支持需求高、住院时间长,需提前规划重症资源。
- 对重症COVID-19患者应密切关注ARDS、机械通气及血管活性药支持等干预指征。
局限性
- 研究间异质性高(院内死亡率I2=96%)。
- 纳入研究均为非随机设计,证据质量受原始研究限制。
- 检索截止至2020年8月1日,未涵盖后续疫情阶段数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has placed unprecedented burden on the delivery of intensive care services worldwide. RESEARCH QUESTION: What is the global point estimate of deaths and risk factors for patients who are admitted to ICUs with severe COVID-19? STUDY DESIGN AND METHODS: In this systematic review and meta-analysis Medline, Embase, and the Cochrane library were searched up to August 1, 2020. Pooled prevalence of participant characteristics, clinical features, and outcome data was calculated with the use of random effects models. Subgroup analyses were based on geographic distribution, study type, quality assessment, sample size, end date, and patient disposition. Studies that reported in-hospital mortality rate of adult patients (age >18 years) with confirmed COVID-19 admitted to an ICU met study eligibility criteria. Critical evaluation was performed with the Newcastle Ottawa Scale for nonrandomized studies. RESULTS: Forty-five studies with 16,561 patients from 17 countries across four continents were included. Patients with COVID-19 who were admitted to ICUs had a mean age of 62.6 years (95% CI, 60.4-64.7). Common comorbidities included hypertension (49.5%; 95% CI, 44.9-54.0) and diabetes mellitus (26.6%; 95% CI, 22.7-30.8). More than three-quarters of cases experienced the development of ARDS (76.1%; 95% CI, 65.7-85.2). Invasive mechanical ventilation was required in 67.7% (95% CI, 59.1-75.7) of case, vasopressor support in 65.9% (95% CI, 52.4-78.4) of cases, renal replacement therapy in 16.9% (95% CI, 12.1-22.2) of cases, and extracorporeal membrane oxygenation in 6.4% (95% CI, 4.1-9.1) of cases. The duration of ICU and hospital admission was 10.8 days (95% CI, 9.3-18.4) and 19.1 days (95% CI, 16.3-21.9), respectively, with in-hospital mortality rate of 28.1% (95% CI, 23.4-33.0; I2 = 96%). No significant subgroup effect was observed. INTERPRETATION: Critically ill patients with COVID-19 who are admitted to the ICU require substantial organ support and prolonged ICU and hospital level care. The pooled estimate of global death from severe COVID-19 is <1 in 3.
引用
- Tan E, Song J, Deane AM, et al. Global Impact of Coronavirus Disease 2019 Infection Requiring Admission to the ICU: A Systematic Review and Meta-analysis. Chest. 2020. PMID: 33069725. doi:10.1016/j.chest.2020.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。